DMSP is the result of the collaboration between the Luxembourg Centre for Systems Biomedicine at the University of Luxembourg (LCSB/UL) and LIH. The platform combines the cellular disease modelling expertise of both institutions with early drug discovery technology.  

The ultimate objective of the DMSP is to provide a diversity of core facilities infrastructure, disease models and expertise, to facilitate the translation of basic scientific discoveries into tangible hit (drug) candidates. Our state-of-the-art platform acts as interface between fundamental biomedical research and high standard drug discovery:  

• to help researchers to develop screenings based on their biological findings  
• to perform High Throughput Screenings (HTS) for them with our compounds or their own library  
• to develop new cellular disease models for phenotypic screening (HCS)  
• to offer phenotypic screenings in established patient-derived cellular models